> top > docs > PMC:7205724 > spans > 10608-11458 > annotations

PMC:7205724 / 10608-11458 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
342 45-53 Species denotes patients Tax:9606
343 88-96 Species denotes patients Tax:9606
344 69-77 Disease denotes COVID-19 MESH:C000657245
345 109-117 Disease denotes COVID-19 MESH:C000657245
353 510-513 Gene denotes CRP Gene:1401
354 352-360 Species denotes patients Tax:9606
355 436-444 Species denotes patients Tax:9606
356 575-583 Species denotes patients Tax:9606
357 593-602 Species denotes SARS-CoV2 Tax:2697049
358 665-674 Species denotes SARS-CoV2 Tax:2697049
359 373-381 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T74 33-39 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T75 201-207 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T76 221-229 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T77 475-485 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T78 553-559 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T79 603-606 Body_part denotes RNA http://purl.org/sig/ont/fma/fma67095
T80 651-657 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T81 737-743 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T82 843-849 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T65 69-77 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T66 109-117 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T67 373-381 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T68 593-597 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T69 665-669 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T112 33-39 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T113 118-119 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T114 133-135 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T115 146-149 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T116 201-207 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T117 348-351 http://purl.obolibrary.org/obo/CLO_0050884 denotes ten
T118 432-435 http://purl.obolibrary.org/obo/CLO_0050884 denotes ten
T119 496-497 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T120 553-559 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T121 651-657 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T122 737-743 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T123 843-849 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T121 277-294 Chemical denotes anti-viral agents http://purl.obolibrary.org/obo/CHEBI_22587

LitCovid-sample-MedDRA

Id Subject Object Predicate Lexical cue meddra_id
T6 150-162 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes investigated http://purl.bioontology.org/ontology/MEDDRA/10062026
T7 475-491 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes lymphocyte count http://purl.bioontology.org/ontology/MEDDRA/10025251

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T82 603-606 Chemical denotes RNA http://purl.obolibrary.org/obo/CHEBI_33697

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T80 69-77 Species denotes COVID-19 NCBItxid:2697049
T81 109-117 Species denotes COVID-19 NCBItxid:2697049
T82 373-381 Species denotes COVID-19 NCBItxid:2697049
T83 593-602 Species denotes SARS-CoV2 NCBItxid:2697049
T84 665-674 Species denotes SARS-CoV2 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T90 0-19 Sentence denotes 4.1.1.2 Rationale:
T91 20-117 Sentence denotes Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19
T92 118-382 Sentence denotes A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19.
T93 383-514 Sentence denotes The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP.
T94 515-684 Sentence denotes Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative.
T95 685-850 Sentence denotes There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma.

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
342 45-53 Species denotes patients Tax:9606
344 69-77 Disease denotes COVID-19 MESH:C000657245
343 88-96 Species denotes patients Tax:9606
345 109-117 Disease denotes COVID-19 MESH:C000657245
354 352-360 Species denotes patients Tax:9606
359 373-381 Disease denotes COVID-19 MESH:C000657245
355 436-444 Species denotes patients Tax:9606
353 510-513 Gene denotes CRP Gene:1401
356 575-583 Species denotes patients Tax:9606
357 593-602 Species denotes SARS-CoV2 Tax:2697049
358 665-674 Species denotes SARS-CoV2 Tax:2697049

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T1222 510-513 Protein denotes CRP https://www.uniprot.org/uniprot/Q5U0J2|https://www.uniprot.org/uniprot/Q07203|https://www.uniprot.org/uniprot/Q01687|https://www.uniprot.org/uniprot/P97315|https://www.uniprot.org/uniprot/P67967|https://www.uniprot.org/uniprot/P67966|https://www.uniprot.org/uniprot/P47875|https://www.uniprot.org/uniprot/P32965|https://www.uniprot.org/uniprot/P21291|https://www.uniprot.org/uniprot/P08462|https://www.uniprot.org/uniprot/A8K268

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T51845 0-7 CD denotes 4.1.1.2
T81264 9-18 NNP denotes Rationale
T56248 18-19 -COLON- denotes :
T77485 20-32 JJ denotes Convalescent
T80710 33-39 NN denotes plasma
T37520 40-44 IN denotes from
T57657 45-53 NNS denotes patients
T22774 54-63 VBN denotes recovered
T85435 64-68 IN denotes from
T50571 69-77 NN denotes COVID-19
T48141 78-81 MD denotes can
T93212 82-87 VB denotes treat
T48287 88-96 NNS denotes patients
T91679 97-101 IN denotes with
T80666 102-108 JJ denotes severe
T17217 109-117 NN denotes COVID-19
T94687 118-119 DT denotes A
T22655 120-125 NN denotes pilot
T19573 126-131 NN denotes study
T23972 132-133 -LRB- denotes [
T55337 133-135 CD denotes 11
T96728 135-136 -RRB- denotes ]
T92410 137-145 RB denotes recently
T26265 146-149 VBZ denotes has
T35997 150-162 VBN denotes investigated
T92380 163-166 DT denotes the
T38590 167-173 NN denotes safety
T37156 174-177 CC denotes and
T24661 178-184 NN denotes effect
T94632 185-187 IN denotes of
T56352 188-200 JJ denotes convalescent
T65134 201-207 NN denotes plasma
T64844 208-212 WDT denotes that
T95987 213-220 VBP denotes contain
T86655 221-229 NN denotes antibody
T45118 230-236 NNS denotes levels
T26321 237-243 JJR denotes higher
T17226 244-248 IN denotes than
T2522 249-250 CD denotes 1
T48589 250-251 -COLON- denotes :
T90182 251-254 CD denotes 640
T89317 255-263 VBN denotes combined
T28925 264-268 IN denotes with
T68950 269-276 JJ denotes regular
T58621 277-287 JJ denotes anti-viral
T22929 288-294 NNS denotes agents
T50644 295-298 CC denotes and
T63224 299-307 JJ denotes standard
T22041 308-318 JJ denotes supportive
T89053 319-323 NN denotes care
T94835 324-326 IN denotes on
T20257 327-335 JJ denotes clinical
T49329 336-344 NNS denotes outcomes
T91601 345-347 IN denotes of
T6238 348-351 CD denotes ten
T3048 352-360 NNS denotes patients
T18696 361-365 IN denotes with
T93206 366-372 JJ denotes severe
T71443 373-381 NN denotes COVID-19
T46997 383-386 DT denotes The
T7672 387-392 NN denotes study
T83098 393-399 VBD denotes showed
T5017 400-408 JJ denotes clinical
T96870 409-420 NN denotes improvement
T42442 421-423 IN denotes of
T61149 424-427 PDT denotes all
T89276 428-431 DT denotes the
T53728 432-435 CD denotes ten
T50396 436-444 NNS denotes patients
T59179 445-456 VBN denotes accompanied
T83510 457-459 IN denotes by
T2183 460-462 DT denotes an
T4240 463-471 NN denotes increase
T18383 472-474 IN denotes in
T99269 475-485 NN denotes lymphocyte
T12131 486-491 NN denotes count
T36613 492-495 CC denotes and
T91622 496-497 DT denotes a
T39579 498-506 NN denotes decrease
T72559 507-509 IN denotes in
T31686 510-513 NN denotes CRP
T20580 515-524 VBG denotes Following
T23341 525-536 NN denotes transfusion
T23846 537-539 IN denotes of
T23496 540-552 JJ denotes convalescent
T68740 553-559 NN denotes plasma
T74721 559-560 -COMMA- denotes ,
T3255 561-564 PDT denotes all
T47829 565-568 DT denotes the
T16466 569-574 CD denotes seven
T26913 575-583 NNS denotes patients
T47643 584-587 WP denotes who
T10299 588-592 VBD denotes were
T19318 593-602 NN denotes SARS-CoV2
T2642 603-606 NN denotes RNA
T76428 607-615 JJ denotes positive
T59448 616-622 IN denotes before
T49967 623-634 NN denotes transfusion
T2352 635-637 IN denotes of
T3020 638-650 JJ denotes convalescent
T57517 651-657 NN denotes plasma
T55829 658-664 VBD denotes turned
T39392 665-674 NN denotes SARS-CoV2
T26456 675-683 JJ denotes negative
T52249 685-690 EX denotes There
T13795 691-695 VBD denotes were
T15563 696-698 DT denotes no
T53693 699-706 NN denotes control
T35357 707-713 NNS denotes groups
T16756 714-723 VBG denotes receiving
T53621 724-736 JJ denotes convalescent
T81904 737-743 NN denotes plasma
T11852 744-749 RB denotes alone
T58859 750-752 CC denotes or
T35171 753-761 JJ denotes standard
T39367 762-769 NN denotes therapy
T20306 770-777 IN denotes without
T63670 778-790 JJ denotes convalescent
T44856 791-798 NN denotes therapy
T15733 799-801 TO denotes to
T71428 802-810 VB denotes evaluate
T29390 811-814 DT denotes the
T54708 815-819 JJ denotes main
T64138 820-826 NN denotes effect
T21425 827-829 IN denotes of
T75685 830-842 JJ denotes convalescent
T78861 843-849 NN denotes plasma
R32394 T22929 T58621 arg1Of agents,anti-viral
R12539 T22929 T50644 arg1Of agents,and
R32883 T89053 T50644 arg2Of care,and
R99734 T89053 T63224 arg1Of care,standard
R84751 T89053 T22041 arg1Of care,supportive
R58957 T48589 T94835 arg1Of :,on
R75573 T49329 T94835 arg2Of outcomes,on
R88677 T81264 T51845 arg1Of Rationale,4.1.1.2
R9567 T81264 T56248 arg1Of Rationale,:
R28137 T80710 T77485 arg1Of plasma,Convalescent
R21152 T80710 T37520 arg1Of plasma,from
R54555 T57657 T37520 arg2Of patients,from
R72924 T57657 T22774 arg2Of patients,recovered
R11993 T22774 T85435 arg1Of recovered,from
R2179 T50571 T85435 arg2Of COVID-19,from
R17226 T80710 T48141 arg1Of plasma,can
R27403 T93212 T48141 arg2Of treat,can
R75667 T80710 T93212 arg1Of plasma,treat
R80215 T48287 T93212 arg2Of patients,treat
R63671 T48287 T91679 arg1Of patients,with
R22614 T17217 T91679 arg2Of COVID-19,with
R57108 T17217 T80666 arg1Of COVID-19,severe
R52082 T19573 T94687 arg1Of study,A
R65194 T19573 T22655 arg1Of study,pilot
R95106 T19573 T23972 arg1Of study,[
R42168 T55337 T23972 arg2Of 11,[
R95339 T96728 T23972 arg3Of ],[
R78448 T35997 T92410 arg1Of investigated,recently
R65706 T19573 T26265 arg1Of study,has
R73941 T35997 T26265 arg2Of investigated,has
R20951 T19573 T35997 arg1Of study,investigated
R83087 T37156 T35997 arg2Of and,investigated
R97536 T37156 T92380 arg1Of and,the
R32731 T38590 T37156 arg1Of safety,and
R69272 T24661 T37156 arg2Of effect,and
R40627 T37156 T94632 arg1Of and,of
R73729 T65134 T94632 arg2Of plasma,of
R7895 T65134 T56352 arg1Of plasma,convalescent
R7377 T37156 T64844 arg1Of and,that
R67249 T37156 T95987 arg1Of and,contain
R70225 T45118 T95987 arg2Of levels,contain
R10830 T45118 T86655 arg1Of levels,antibody
R61261 T45118 T26321 arg1Of levels,higher
R50969 T26321 T17226 arg1Of higher,than
R4008 T48589 T17226 arg2Of :,than
R30054 T2522 T48589 arg1Of 1,:
R45762 T90182 T48589 arg2Of 640,:
R9970 T48589 T89317 arg2Of :,combined
R87348 T89317 T28925 arg1Of combined,with
R60332 T50644 T28925 arg2Of and,with
R69387 T22929 T68950 arg1Of agents,regular
R98484 T49329 T20257 arg1Of outcomes,clinical
R34116 T49329 T91601 arg1Of outcomes,of
R5522 T3048 T91601 arg2Of patients,of
R74118 T3048 T6238 arg1Of patients,ten
R51409 T3048 T18696 arg1Of patients,with
R40479 T71443 T18696 arg2Of COVID-19,with
R90019 T71443 T93206 arg1Of COVID-19,severe
R55615 T7672 T46997 arg1Of study,The
R40867 T7672 T83098 arg1Of study,showed
R64658 T96870 T83098 arg2Of improvement,showed
R66056 T96870 T5017 arg1Of improvement,clinical
R52864 T96870 T42442 arg1Of improvement,of
R70060 T50396 T42442 arg2Of patients,of
R51479 T50396 T61149 arg1Of patients,all
R50628 T50396 T89276 arg1Of patients,the
R30895 T50396 T53728 arg1Of patients,ten
R56320 T36613 T59179 arg1Of and,accompanied
R2541 T50396 T59179 arg2Of patients,accompanied
R80186 T36613 T83510 arg2Of and,by
R38806 T4240 T2183 arg1Of increase,an
R9880 T4240 T18383 arg1Of increase,in
R77420 T12131 T18383 arg2Of count,in
R60391 T12131 T99269 arg1Of count,lymphocyte
R95922 T4240 T36613 arg1Of increase,and
R85485 T39579 T36613 arg2Of decrease,and
R67798 T39579 T91622 arg1Of decrease,a
R82541 T39579 T72559 arg1Of decrease,in
R48725 T31686 T72559 arg2Of CRP,in
R83808 T55829 T20580 arg1Of turned,Following
R25087 T23341 T20580 arg2Of transfusion,Following
R66336 T23341 T23846 arg1Of transfusion,of
R9016 T68740 T23846 arg2Of plasma,of
R27767 T68740 T23496 arg1Of plasma,convalescent
R79010 T55829 T74721 arg1Of turned,","
R49789 T26913 T3255 arg1Of patients,all
R98083 T26913 T47829 arg1Of patients,the
R36266 T26913 T16466 arg1Of patients,seven
R42101 T26913 T47643 arg1Of patients,who
R24725 T26913 T10299 arg1Of patients,were
R12375 T2642 T10299 arg2Of RNA,were
R19448 T2642 T19318 arg1Of RNA,SARS-CoV2
R23710 T2642 T76428 arg1Of RNA,positive
R34529 T10299 T59448 arg1Of were,before
R60141 T49967 T59448 arg2Of transfusion,before
R2931 T49967 T2352 arg1Of transfusion,of
R3822 T57517 T2352 arg2Of plasma,of
R20207 T57517 T3020 arg1Of plasma,convalescent
R30096 T26913 T55829 arg1Of patients,turned
R66579 T26456 T55829 arg2Of negative,turned
R14919 T26456 T39392 arg1Of negative,SARS-CoV2
R49718 T26913 T26456 arg1Of patients,negative
R70070 T52249 T13795 arg1Of There,were
R68506 T35357 T13795 arg2Of groups,were
R94657 T35357 T15563 arg1Of groups,no
R49835 T35357 T53693 arg1Of groups,control
R88768 T35357 T16756 arg1Of groups,receiving
R7103 T58859 T16756 arg2Of or,receiving
R65241 T81904 T53621 arg1Of plasma,convalescent
R80896 T81904 T11852 arg1Of plasma,alone
R48507 T81904 T58859 arg1Of plasma,or
R74990 T39367 T58859 arg2Of therapy,or
R57531 T39367 T35171 arg1Of therapy,standard
R26123 T16756 T20306 arg1Of receiving,without
R11811 T44856 T20306 arg2Of therapy,without
R59105 T44856 T63670 arg1Of therapy,convalescent
R40530 T71428 T15733 arg1Of evaluate,to
R29016 T16756 T15733 modOf receiving,to
R33735 T64138 T71428 arg2Of effect,evaluate
R2474 T64138 T29390 arg1Of effect,the
R56840 T64138 T54708 arg1Of effect,main
R22469 T64138 T21425 arg1Of effect,of
R7749 T78861 T21425 arg2Of plasma,of
R22133 T78861 T75685 arg1Of plasma,convalescent

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T74 33-39 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T75 201-207 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T76 221-229 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T77 475-485 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T78 553-559 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T79 603-606 Body_part denotes RNA http://purl.org/sig/ont/fma/fma67095
T80 651-657 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T81 737-743 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T82 843-849 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T62 69-77 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T63 109-117 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T64 373-381 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T65 593-602 Disease denotes SARS-CoV2 http://purl.obolibrary.org/obo/MONDO_0100096
T66 665-674 Disease denotes SARS-CoV2 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T90 0-19 Sentence denotes 4.1.1.2 Rationale:
T91 20-117 Sentence denotes Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19
T92 118-382 Sentence denotes A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19.
T93 383-514 Sentence denotes The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP.
T94 515-684 Sentence denotes Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative.
T95 685-850 Sentence denotes There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma.